Abstract: The present invention relates to an antigen-binding molecule comprising a heavy chain variable region comprising a heavy-chain complementarity-determining region 1 (HCDR1) comprising an amino acid sequence represented by Sequence No. 1, an HCDR2 comprising an amino acid sequence represented by Sequence No. 2, and an HCDR3 comprising an amino acid sequence represented by Sequence No. 3; a light-chain variable region comprising a light-chain complementarity-determining region 1 (LCDR1) comprising an amino acid sequence represented by Sequence No. 4, an LCDR2 comprising an amino acid sequence represented by Sequence No. 5, and an LCDR3 comprising an amino acid sequence represented by Sequence No. 6; wherein the antigen-binding molecule is a T cell receptor (TCR); and to a cell line expressing the same.

Abstract: Determining, in a sample, the presence and/or amount of pluripotent stem cells. A sample suspected of containing one or more pluripotent stem cells is provided. The sample with a fluorescent compound is contacted under conditions that allow binding of the fluorescent compound to the pluripotent stem cells, where the fluorescent compound is a fluorescent compound of formula (I) or a pharmaceutically acceptable salt thereof. The presence and/or amount of the pluripotent stem cells is determined by measuring the fluorescence of the cells following the contacting.

Abstract: The present invention provides fluorescent compounds of formula (I) as disclosed herein or pharmaceutically acceptable salts thereof. Further provided are uses of said fluorescent compounds in methods of determining, in a sample, the presence and/or amount of pluripotent stem cells or cells undergoing reprogramming to become induced pluripotent stem cells.

Abstract: The present invention provides fluorescent compounds of formula (I) as disclosed herein or pharmaceutically acceptable salts there-of. Further provided are uses of said fluorescent compounds in methods of determining, in a sample, the presence and/or amount of pluripotent stem cells or cells undergoing reprogramming to become induced pluripotent stem cells.

Abstract: The present invention relates to a family of fluorescent compounds based on the BODIPY scaffold, and methods for the preparation of said compounds. The present invention further relates to the use of said compounds for the detection of bacterial biofilms, wherein the bacterial biofilm comprises Pseudomonas aeruginosa and the compound specifically binds to a Fap protein of Pseudomonas aeruginosa, or wherein the compound specifically binds to bacterial cells that contain high levels of cyclic-di-guanosine-monophosphate (c-di-GMP).

Abstract: There is provided a method of preparing a surface enhanced Raman spectroscopy (SERS) particle comprising the step of encapsulating a plurality of Raman molecules on the surface of a metallic core with a biocompatible protective shell at an elevated temperature selected to decrease the encapsulation time by more than one-fold relative to an encapsulation performed at 20° C.

Abstract: The present invention relates to a family of fluorescent compounds based on the BODIPY scaffold, and methods for the preparation of said compounds. The present invention further relates to the use of said compounds for the detection of bacterial biofilms, wherein the bacterial biofilm comprises Pseudomonas aeruginosa and the compound specifically binds to a Fap protein of Pseudomonas aeruginosa, or wherein the compound specifically binds to bacterial cells that contain high levels of cyclic-di-guanosine-monophosphate (c-di-GMP).

Abstract: The present invention relates to compounds of Formula (I) as defined herein as well as conjugates comprising said compounds and pharmaceutical compositions comprising said compounds or conjugates. Also encompassed are methods for selectively detecting oligomeric proteins or peptides associated with a conformational disorder in a sample, and methods for diagnosing or treating a conformational disorder associated with protein or peptide oligomers in a subject.

Abstract: The present invention relates to the synthesis and characterization of an Abcg2 targeted fluorescence probe (compound of formula I), as well as live imaging of neural stem/progenitor cells (NSPCs) and isolation of live NSPCs using said probe.

Abstract: The invention relates to compounds of formula (I) or derivatives, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites or prodrugs thereof, in which the substituents are as defined in the specification. These compounds may be useful as insulin sensors; in insulin secretion studies and as probes for insulin detection.

Abstract: Technologies are generally described for controlling remote display. In some examples, a method for controlling a remote display device using a handheld computing device includes receiving, by a handheld computing device, one or more data from one or more remote display devices over a wireless communication network, selecting a remote display device based on the received data and sending a control signal to the selected remote display device.

Abstract: A library of novel amino-triazolyl-BODIPY compounds is described. Particular compounds of the library serve as selective fluorescent probes for human serum albumin (HSA) and for live primary neurons. The fluorescent probe for HSA binds uniquely and specifically to the fatty acid site 1 of HSA, and thus proves a valuable and unique probe for drugs that bind to such a site on HSA. Methods of synthesis for the library compounds are also described.

Abstract: The present invention is directed to a fluorescence compound represented by structural Formula (I), with specificity to neural stem cells: (I), or a pharmaceutically acceptable salt thereof. The variables for structural Formula (I) are defined herein. Also described are methods for detection of beta cells, pancreatic islets and microglia cells, comprising using a compound of structural Formula (I) or pharmaceutically acceptable salts thereof. Compounds of structural Formula (I) can also differentiate healthy pancreatic islet cells from diabetic pancreatic islet cells.

Abstract: The present invention is directed to a novel family of fluorophores based on the BODIPY scaffold, and methods for their synthesis. The BODIPY-based fluorophores disclosed herein are used for the selective visualization of cells that exist in the M-phase of the cell cycle. The present invention further relates to methods for the image-based monitoring of mitotic progression in live cells.

Abstract: A method for sorting pluripotent cells using a compound which is eliminated from the pluripotent cells through the MDR1 transporter.

Abstract: The present invention relates to Caffeine Orange, a novel aqueous-phase fluorescence turn-on sensor for caffeine that is structurally based on a BODIPY-scaffold. The present invention further provides for methods of detecting and measuring caffeine in aqueous media. A change in the intensity or visible color of the fluorescence is detectable by either a fluorimeter or by the naked eye. The methods disclosed herein provide for the utilization of a reverse-phase SPE column, optionally as a component in a syringe or a microfluidics-based automation detection system. The invention further provides for the solid phase extraction of an analyte such as caffeine from a liquid medium, the extraction occurring on a microfluidic disc.

Abstract: The present invention discloses a series of alkylamino BODIPY dyes, methods for preparing a library of alkyl-amino BODIPY dyes via solid-phase synthesis, and the use of the alkyl-amino BODIPY dyes as fluorescent sensors for protein detection, cell imaging and cytometry applications, and staining of certain cell line.

Abstract: The present invention provides a method for screening a diabetes treating agent comprising the following steps: (a) preparing cells inside a culture medium; (b) treating the culture medium with a test substance; (c) treating the result of step (b) with a glucose derivative which is not metabolized; and (d) measuring the glucose derivative which has flowed into the cells, wherein the test substance is determined to be a diabetes treating agent if the test substance accelerates uptake of the glucose derivative in the cells. Therefore, the described pharmaceutical composition, including a triazin-based compound as an active ingredient, can be useful for application in preventing or treating diabetes.

Abstract: The present invention is directed to a novel family of fluorophores based on the BODIPY scaffold, and methods for their synthesis. The BODIPY-based fluorophores disclosed herein are used for the selective visualization of cells that exist in the M-phase of the cell cycle. The present invention further relates to methods for the image-based monitoring of mitotic progression in live cells.

Abstract: A compound of structural formula (I): The values and alternative values are as defined herein. The invention also includes biosensors comprising nanoparticles functionalized with a compound of structural formula (I). Also described is a method for labeling a biomolecule using a compound of structural formula (I) and a method of detecting a target biomolecule using a compound of structural formula (I) or a biosensor of the invention.